{"id":2901,"date":"2026-09-03T00:00:00","date_gmt":"2026-09-03T04:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2901"},"modified":"2026-09-04T16:53:49","modified_gmt":"2026-09-04T20:53:49","slug":"etentamig-meets-both-cervino-endpoints","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2901","title":{"rendered":"Etentamig Meets Both CERVINO Endpoints"},"content":{"rendered":"

Company:<\/strong> AbbVie · Drug:<\/strong> Etentamig (BCMAxCD3 Bispecific) · Trial:<\/strong> CERVINO (Phase III) · Indication:<\/strong> Relapsed\/Refractory Multiple Myeloma · Date:<\/strong> September 3, 2026<\/p>\n

\"Etentamig<\/p>\n

Summary<\/h4>\n

AbbVie’s investigational BCMAxCD3 bispecific etentamig met both dual primary endpoints in the 393-patient Phase III CERVINO trial. Objective response was 74.0% versus 45.7% with investigator-selected standard therapy, and progression-free survival favored etentamig with a hazard ratio of 0.40. The result is clinically and regulatorily material; overall survival, infection burden and community-care differentiation remain incompletely resolved.<\/p>\n

What Happened<\/h4>\n

CERVINO randomized triple-class-exposed relapsed\/refractory multiple-myeloma patients 1:1 after at least two prior lines. Standard therapy comprised carfilzomib-dexamethasone, elotuzumab-pomalidomide-dexamethasone, or selinexor-bortezomib-dexamethasone. Patients had received a median of three prior lines, and median follow-up at the first planned efficacy interim analysis was 11.4 months. ORR was 74.0% versus 45.7% (P<0.0001); PFS HR was 0.40 (95% CI 0.29-0.54; P<0.0001). Twelve-month OS was 87.9% versus 72.0% (HR 0.48), but the prespecified OS efficacy boundary was not crossed. The monitoring committee recommended unblinding based on the primary-endpoint result. Etentamig used one step-up dose followed by once-monthly treatment. Grade 3\/4 infections occurred in 27.7% versus 19.2%; grade 5 infections were 1.5% versus 3.1%. CRS occurred in 28.3%, predominantly grade 1, with no grade 3+ cases reported; one grade-1 ICANS case occurred. Full data are scheduled for September 25, and regulatory discussions, not an application or approval, are the next disclosed step.<\/p>\n

Deep Analysis<\/h4>\n

The efficacy effect is unusually large against active investigator-choice regimens, and concordant ORR and PFS reduce the risk that benefit reflects only response ascertainment. However, an open-label design, immature OS, incomplete depth\/duration-of-response reporting and trial-specific comparator selection limit cross-trial claims against approved BCMA bispecifics or CAR-T products. Etentamig combines a low-affinity CD3 arm, bivalent high-avidity BCMA binding and retained FcRn recycling, aiming to preserve tumor-cell avidity while moderating cytokine activation and extending dosing interval; clinical correlations of those structural features are not fully established, so low-grade CRS and monthly dosing should be treated as observed attributes rather than proven mechanistic causation. The outpatient thesis is plausible but not demonstrated by topline data alone. Community use will depend on infection prophylaxis, immunoglobulin monitoring, early-cycle observation, manufacturing consistency, reimbursement and comparison with teclistamab, elranatamab, linvoseltamab and cellular therapies; higher grade 3\/4 infection frequency than standard therapy remains a meaningful counterweight.<\/p>\n

Company and Product Background<\/h4>\n

AbbVie is a global biopharmaceutical company with a hematologic-oncology portfolio spanning antibodies, small molecules and cell therapy. Etentamig, formerly ABBV-383\/TNB-383B, is a second-generation BCMAxCD3 bispecific antibody developed for multiple myeloma. BCMA is expressed on plasma cells and supports myeloma-cell survival. Bispecific antibodies bind BCMA and CD3 to form an immune synapse and redirect T-cell cytotoxicity. Risks include CRS, infections, cytopenias, neurotoxicity and prolonged hypogammaglobulinemia. CERVINO tests etentamig after exposure to proteasome inhibitors, immunomodulators and anti-CD38 antibodies. Translation into practice depends on benefit relative to existing bispecifics, CAR-T availability, sequencing, resistance after prior BCMA therapy and the ability to manage infections outside specialty centers.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Trial<\/td>\nCERVINO, 393 patients, randomized Phase III vs. investigator-choice standard therapy<\/td>\n<\/tr>\n
Efficacy<\/td>\nORR 74.0% vs. 45.7% (P<0.0001); PFS HR 0.40 (P<0.0001)<\/td>\n<\/tr>\n
Overall Survival<\/td>\n12-month OS 87.9% vs. 72.0% (HR 0.48); prespecified boundary not crossed<\/td>\n<\/tr>\n
Safety<\/td>\nGrade 3\/4 infections 27.7% vs. 19.2%; CRS 28.3% (mostly grade 1, no grade 3+)<\/td>\n<\/tr>\n
Next Steps<\/td>\nFull data September 25; regulatory discussions planned, no filing yet<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> A large, statistically robust randomized PFS and ORR effect against active investigator-choice regimens, combined with low-grade CRS and simple monthly dosing, supports a differentiated late-line BCMA bispecific with operationally simpler community administration.<\/p>\n

Bear case:<\/strong> Higher grade 3\/4 infection rates than standard therapy, immature overall survival that has not yet crossed its efficacy boundary, and an open-label design with trial-specific comparator selection limit confident cross-trial claims against approved BCMA bispecifics and CAR-T products.<\/p>\n

InSilens Take<\/h4>\n

This is a 5\/5 positive clinical signal. Both prespecified primary endpoints crossed with a large randomized PFS effect. The conclusion remains bounded: etentamig is investigational, OS is not yet statistically established, and monthly dosing does not itself prove community readiness.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 5\/5 · Direction:<\/strong> Positive · Confidence:<\/strong> High on facts, Moderate on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

AbbVie’s investigational BCMAxCD3 bispecific etentamig met both dual primary endpoints in the 393-patient Phase III CERVINO trial. Objective response was 74.0% versus 45.7% with investigator-selected standard therapy, and progression-free survival favored etentamig with a…<\/p>\n","protected":false},"author":1,"featured_media":2918,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[53,557,556,30],"class_list":["post-2901","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-abbvie","tag-bcma","tag-etentamig","tag-multiple-myeloma"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2901","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2901"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2901\/revisions"}],"predecessor-version":[{"id":2923,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2901\/revisions\/2923"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2918"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2901"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2901"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2901"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}